|
Glenmark Pharmaceuticals Limited [Glenmark] is an India-based growing pharmaceutical company headquartered at Mumbai [formerly, Bombay]. Incorporated in 1977, the Company is focused on the manufacture and marketing of formulation products and active pharmaceutical ingredients [API] in India as well as globally and enjoys a diversified and growing presence in regulated and developing international markets. Over the past five years, the Company has also catalysed its growth through investment in dedicated research and development including cutting-edge New Chemical Entity [NCE] research. Glenmark is amongst the few Indian Pharmaceutical Companies to have taken initiative to invest proactively in original drug discovery research. In a span of three years Glenmark's R&D team has also successfully developed one Novel Drug Lead for Asthma and COPD. This PDE-4 inhibitor has successfully completed Phase I clinical trials in the UK and has been licensed out to Forest Laboratories, USA for North America and Teijin Pharma Limited for the Japanese territory.
|
